Page 71 - Diamicron MR MIG Cycle 2(20-21) Final

2426 ZACCARDI ET AL.

11. Group AC, Patel A, MacMahon S, et al. Intensive blood glucose con- 22. Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treat-
trol and vascular outcomes in patients with type 2 diabetes. N Engl J ment intensification increases the risks of cardiovascular events in
Med. 2008;358(24):2560-2572. patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100.
12. Sharma M, Beckley N, Nazareth I, Petersen I. Effectiveness of 23. Cefalu WT, Rosenstock J, LeRoith D, Blonde L, Riddle MC. Getting to
sitagliptin compared to sulfonylureas for type 2 diabetes mellitus the “heart” of the matter on diabetic cardiovascular disease: “thanks
inadequately controlled on metformin: a systematic review and meta- for the memory”. Diabetes Care. 2016;39(5):664-667.
analysis. BMJ Open. 2017;7(10):e017260. 24. Harrower AD. Comparison of efficacy, secondary failure rate, and
13. Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs complications of sulfonylureas. J Diabetes Complications. 1994;8(4):
glimepiride on major adverse cardiovascular outcomes in patients 201-203.
with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 25. Satoh J, Takahashi K, Takizawa Y, et al. Secondary sulfonylurea fail-
2019;322(12):1155-1166. ure: comparison of period until insulin treatment between diabetic
14. Douros A, Yin H, Yu OHY, Filion KB, Azoulay L, Suissa S. Pharma- patients treated with gliclazide and glibenclamide. Diabetes Res Clin
cologic differences of sulfonylureas and the risk of adverse cardio- Pract. 2005;70(3):291-297.
vascular and hypoglycemic events. Diabetes Care. 2017;40(11): 26. Noh Y, Lee S, Shin S. Durability of initial antidiabetic monotherapy
1506-1513. and subsequent treatment adjustment patterns among newly treated
15. Langan SM, Schmidt SA, Wing K, et al. The reporting of studies type 2 diabetes patients. Ther Clin Risk Manag. 2018;14:1563-1571.
conducted using observational routinely collected health data 27. Mamza J, Mehta R, Donnelly R, Idris I. Important differences in the
statement for pharmacoepidemiology (RECORD-PE). BMJ. 2018; durability of glycaemic response among second-line treatment
363:k3532. options when added to metformin in type 2 diabetes: a retrospective
16. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, cohort study. Ann Med. 2016;48(4):224-234.
Brookhart MA. High-dimensional propensity score adjustment in 28. Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ. Estimating the
studies of treatment effects using health care claims data. Epidemiol- effect of sulfonylurea on HbA1c in diabetes: a systematic review and
ogy. 2009;20(4):512-522. meta-analysis. Diabetologia. 2013;56(5):973-984.
17. Zhang Y, Hong J, Chi J, Gu W, Ning G, Wang W. Head-to-head com- 29. Yu O, Azoulay L, Yin H, Filion KB, Suissa S. Sulfonylureas as initial
parison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a treatment for type 2 diabetes and the risk of severe hypoglycemia.
meta-analysis from randomized clinical trials. Diabetes Metab Res Rev. Am J Med. 2018;131(3):317 e311-317 e322.
2014;30(3):241-256. 30. Clemens KK, McArthur E, Dixon SN, Fleet JL, Hramiak I, Garg AX.
18. Vashisht R, Jung K, Schuler A, et al. Association of hemoglobin A1c The hypoglycemic risk of glyburide (glibenclamide) compared with
levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, modified-release gliclazide. Can J Diabetes. 2015;39(Suppl 4):32-40.
and thiazolidinediones in patients with type 2 diabetes treated
with metformin: analysis from the observational health data sci-
ences and informatics initiative. JAMA Netw Open. 2018;1(4): SUPPORTING INFORMATION
e181755. Additional supporting information may be found online in the
19. Bain S, Druyts E, Balijepalli C, et al. Cardiovascular events and all-
cause mortality associated with sulphonylureas compared with other Supporting Information section at the end of this article.
antihyperglycaemic drugs: a Bayesian meta-analysis of survival data.
Diabetes Obes Metab. 2017;19(3):329-335.
20. Hou L, Zhao T, Liu Y, Zhang Y. Efficacy and safety of sitagliptin com- How to cite this article: Zaccardi F, Jacquot E, Cortese V, et al.
pared with sulfonylurea therapy in patients with type 2 diabetes Comparative effectiveness of gliclazide modified release
showing inadequately controlled glycosylated hemoglobin with met- versus sitagliptin as second-line treatment after metformin
formin monotherapy: a meta-analysis. Exp Ther Med. 2015;9(4):1528- monotherapy in patients with uncontrolled type 2 diabetes.
1536.
21. Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 dia- Diabetes Obes Metab. 2020;22:2417–2426. https://doi.org/
betes: impact of early glycemic control on future complications (the 10.1111/dom.14169
Diabetes & Aging Study). Diabetes Care. 2019;42(3):416-426.